Finance entity
All 2 tracked stories fall under one category: earnings. Profound Medical is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 2 stories. Each story carries 3.5 original sources on average, compared with 2.7 for the broader beat in this window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: earnings. Profound Medical is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 2 stories. Each story carries 3.5 original sources on average, compared with 2.7 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.2 in the same window. We currently track 2 Finance stories that mention Profound Medical, published between March 5, 2026 and March 6, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 193 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Profound Medical. Shared-story counts are live from our verified record — not editorial picks.
PROF Break-even
Target window for Profound Medical to reach cash-flow neutrality.
Kura NDA Submission
Anticipated filing for ziftomenib with the FDA.
Q4 Earnings Release
Both companies report pivotal year-end results.
CPT Code Activation
Category 1 CPT codes for TULSA-PRO go live in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
A cluster of mid-cap and small-cap companies, led by Rumble and Atea Pharmaceuticals, released fourth-quarter and full-year 2025 results, signaling a period of strategic transition. The reports highlight a divergence between high-growth digital infrastructure and the clinical-stage healthcare sector as firms navigate the post-2024 economic landscape.
Profound Medical is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
